Get the Stockscreener App
30.58
6.65%
-2.18
Spyre Therapeutics Inc stock is traded at $30.58, with a volume of 888.69K.
It is down -6.65% in the last 24 hours and up +7.68% over the past month.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
See More
Previous Close:
$32.76
Open:
$32.76
24h Volume:
888.69K
Relative Volume:
0.97
Market Cap:
$2.37B
Revenue:
$688.00K
Net Income/Loss:
$-170.19M
P/E Ratio:
-10.03
EPS:
-3.0495
Net Cash Flow:
$-154.68M
1W Performance:
-7.16%
1M Performance:
+7.68%
6M Performance:
+97.29%
1Y Performance:
+28.22%
1-Day Range:
$30.11
$33.31
1-Week Range:
$30.11
$33.31
52-Week Range:
$10.91
$35.31
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Name
Spyre Therapeutics Inc
Sector
Industry
Phone
(617) 651-5940
Address
221 CRESCENT STREET, WALTHAM
Compare SYRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
30.58 | 2.54B | 688.00K | -170.19M | -154.68M | -3.0495 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Mizuho | Outperform |
| Dec-17-25 | Initiated | Citigroup | Buy |
| Sep-26-25 | Initiated | Deutsche Bank | Buy |
| Apr-08-25 | Initiated | Leerink Partners | Outperform |
| Mar-18-25 | Initiated | Wolfe Research | Outperform |
| Sep-04-24 | Initiated | Wedbush | Outperform |
| Jul-16-24 | Initiated | Evercore ISI | Outperform |
| May-02-24 | Initiated | Robert W. Baird | Outperform |
| Mar-01-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Dec-11-23 | Initiated | Guggenheim | Buy |
| Dec-11-23 | Initiated | Jefferies | Buy |
| May-04-20 | Initiated | Piper Sandler | Overweight |
| Mar-21-19 | Initiated | JP Morgan | Overweight |
| Sep-04-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Apr-24-18 | Initiated | Evercore ISI | Outperform |
| Mar-14-18 | Reiterated | Needham | Buy |
View All
Spyre Therapeutics Inc Stock (SYRE) Latest News
Spyre Therapeutics stock sinks 7% today: what’s pressuring SYRE and what investors watch next - ts2.tech
Spyre Therapeutics (NASDAQ:SYRE) Shares Down 6.5%Time to Sell? - MarketBeat
Spyre Therapeutics (SYRE) Sees Significant Decline in Stock Value - GuruFocus
Spyre Therapeutics: Validated Targets, Optimized Delivery - Seeking Alpha
CapEx per share of Spyre Therapeutics, Inc – SWB:3920 - TradingView — Track All Markets
Spyre Therapeutics Slides Despite Bullish Long-Term Hopes - TipRanks
Street Watch: Is Spyre Therapeutics Inc stock a contrarian buyQuarterly Market Summary & Daily Entry Point Trade Alerts - moha.gov.vn
Trend Recap: What makes Spyre Therapeutics Inc. stock attractive to growth fundsJuly 2025 Earnings & Detailed Earnings Play Alerts - Улправда
Why Spyre Therapeutics Inc. stock is recommended by analystsJuly 2025 Chart Watch & Safe Entry Momentum Stock Tips - Улправда
Will Spyre Therapeutics Inc. stock deliver shareholder value2025 Stock Rankings & Momentum Based Trading Ideas - Улправда
How geopolitical tensions affect Spyre Therapeutics Inc. stock2025 Biggest Moves & Technical Entry and Exit Tips - Улправда
How Spyre Therapeutics Inc. stock responds to policy changesSwing Trade & Fast Gaining Stock Strategy Reports - Улправда
Spyre Therapeutics (NASDAQ:SYRE) Upgraded at Mizuho - MarketBeat
Citigroup Initiates Coverage on Spyre Therapeutics (NASDAQ:SYRE) - MarketBeat
Why Spyre Therapeutics Inc. stock remains resilient2025 Top Gainers & Safe Entry Trade Reports - Улправда
Mizuho Initiates Coverage of Spyre Therapeutics (SYRE) with Outperform Recommendation - Nasdaq
Mizuho Initiates Spyre Therapeutics at Outperform With $53 Price Target - marketscreener.com
Mizuho Initiates Coverage on Spyre Therapeutics (SYRE) with 'Out - GuruFocus
Biotech Momentum Carries After-Hours Trading Gains - RTTNews
Analysts Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) Target Price at $52.33 - Defense World
Citigroup Initiates Coverage of Spyre Therapeutics (SYRE) with Buy Recommendation - Nasdaq
Mizuho initiates Spyre Therapeutics stock with Outperform rating By Investing.com - Investing.com Canada
SYRE: Citigroup Initiates Coverage with a 'Buy' Rating and $64 P - GuruFocus
Citigroup Initiates Spyre Therapeutics at Buy With $64 Price Target - marketscreener.com
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
60,372,927 Common Stock of Spyre Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2025. - marketscreener.com
Certain Series A Preferred Stock of Spyre Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2025. - marketscreener.com
Certain Series B Preferred Stock of Spyre Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2025. - marketscreener.com
Spyre Therapeutics stock hits 52-week high at 35.0 USD By Investing.com - Investing.com Australia
Spyre Therapeutics stock hits 52-week high at 35.0 USD - Investing.com
Spyre Therapeutics (SYRE): Assessing Valuation After a Sharp Momentum-Driven Share Price Surge - Yahoo Finance
Spyre Therapeutics (NASDAQ:SYRE) Hits New 52-Week HighShould You Buy? - MarketBeat
A Short Squeeze Could Send This Little-Known Biotech Stock Soaring - inkl
Affinity Asset Advisors LLC Raises Stock Holdings in Spyre Therapeutics, Inc. $SYRE - MarketBeat
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Spyre Therapeutics (NASDAQ: SYRE) issues 20,300-share inducement stock options - Stock Titan
Spyre Therapeutics (NASDAQ:SYRE) CEO Cameron Turtle Sells 15,000 Shares - MarketBeat
Will Spyre Therapeutics Inc. (3920) stock see insider accumulationEarnings Overview Report & Fast Momentum Stock Entry Tips - Newser
Spyre Therapeutics (NASDAQ:SYRE) Trading Up 7.2%Still a Buy? - MarketBeat
Spyre Therapeutics CEO Turtle Cameron sells $435k in stock By Investing.com - Investing.com UK
Spyre Therapeutics: A New Era Unfolds? - timothysykes.com
A significant driver of top-line growth: Spyre Therapeutics Inc (SYRE) - setenews.com
Spyre Therapeutics stock reaches 52-week high at 30.56 USD By Investing.com - Investing.com Nigeria
Spyre Therapeutics stock reaches 52-week high at 30.56 USD - Investing.com
Is Spyre Therapeutics Inc. (3920) stock at risk of policy regulation2025 Valuation Update & Fast Exit and Entry Trade Guides - Newser
Why Spyre Therapeutics Inc. stock is in analyst buy zone2025 AllTime Highs & Detailed Earnings Play Strategies - Newser
Spyre Therapeutics (NASDAQ:SYRE) Sets New 12-Month High on Analyst Upgrade - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Upgraded by Jones Trading to Buy Rating - MarketBeat
What is the fair value of Spyre Therapeutics Inc. stock nowRate Hike & Verified Momentum Stock Watchlist - Newser
Spyre Therapeutics (NASDAQ:SYRE) Upgraded by Jones Trading to “Buy” Rating - Defense World
Spyre Therapeutics Inc Stock (SYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):